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Hematopoietic stem and progenitor cells (HSPCs) are multipotent stem cells that have 
been harnessed as a curative therapy for patients with hematological malignancies. 
Notably, the discovery that HSPCs are endowed with immunoregulatory properties 
suggests that HSPC-based therapeutic approaches may be used to treat autoimmune 
diseases. Indeed, infusion with HSPCs has shown promising results in the treatment of 
type 1 diabetes (T1D) and remains the only “experimental therapy” that has achieved a 
satisfactory rate of remission (nearly 60%) in T1D. Patients with newly diagnosed T1D 
have been successfully reverted to normoglycemia by administration of autologous 
HSPCs in association with a non-myeloablative immunosuppressive regimen. However, 
this approach is hampered by a high incidence of adverse effects linked to immuno-
suppression. Herein, we report that while the use of autologous HSPCs is capable of 
improving C-peptide production in patients with T1D, ex vivo modulation of HSPCs 
with prostaglandins (PGs) increases their immunoregulatory properties by upregulating 
expression of the immune checkpoint-signaling molecule PD-L1. Surprisingly, CXCR4 
was upregulated as well, which could enhance HSPC trafficking toward the inflamed 
pancreatic zone. When tested in murine and human in  vitro autoimmune assays, 
PG-modulated HSPCs were shown to abrogate the autoreactive T cell response. The 
use of PG-modulated HSPCs may thus provide an attractive and novel treatment of 
autoimmune diabetes.
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Table 2 | Clinical characteristics of patients with T1D and of healthy controls 
included in the PGs library screening.
Patient characteristics
Number of patients included n = 24
Age (years ± SEM) 58.2 ± 11.6
Gender (M/F) 16/8
BMI (kg/m2 ± SEM) 20.7 ± 0.5
EIR (UI) 18.3 ± 5.4
Concomitant treatment Levothyroxine (n = 8), statin (n = 5)
healthy control characteristics
Number of individuals included n = 5
Age (years ± SEM) 40.8 ± 6.4
Gender (M/F) 2/3
T1D, type 1 diabetes; BMI, body mass index; EIR, exogenous insulin requirement units; 
PGs, prostaglandins.
Table 1 | Baseline demographic and clinical characteristics of patients with 
T1D treated with autologous non-myeloablative hematopoietic stem cell 
transplantation in two AHCST cohorts.
Patient characteristics
Number of patients included n = 36
Age (years ± SEM) 22.4 ± 0.9
Gender (M/F) 27/9
BMI (kg/m2 ± SEM) 20.7 ± 0.5
HbA1c (mmol/mol ± SEM) 86.6 ± 6.4
C-peptide (ng/ml ± SEM) 0.73 ± 0.06
Autoantibodies (% of patients)
GAD 86
Other (IAA, IA-2A, ICA) 17
DKA or DK history (% of patients)
No DKA/DK 67
DKA 28
DK 5
T1D, type 1 diabetes; AHSCT, autologous hematopoietic stem and progenitor 
cell transplantation; BMI, body mass index; GAD, glutamic acid decarboxylase 
autoantibodies; ICA, islet cell cytoplasmic autoantibodies; IA-2A, insulinoma-2-
associated autoantibodies; IAA, insulin autoantibodies; DKA, diabetic ketoacidosis;  
DK, diabetic ketosis.
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inTrODUcTiOn
Encouraging results of previous pilot trials suggest that autologous 
hematopoietic stem and progenitor cell transplantation (AHSCT) 
may be a relevant alternative therapeutic option to immunosup-
pressive drugs in the treatment of several refractory autoimmune 
disorders (1, 2). Over 3,000 transplants using AHSCT have been 
performed worldwide with a very high safety profile (2, 3). We 
recently demonstrated that AHSCT could induce long-term, drug 
free, and symptoms-free remission in patients newly diagnosed 
with type 1 diabetes (T1D). Insulin independence was achieved 
in nearly 60% of treated subjects at 6 months, with 40% show-
ing sustained insulin-free remission over 4  years following the 
procedure (4). The aim behind the use of AHSCT is to suppress 
autoreactive immune cells, while allowing for de novo generation 
of a naïve immune compartment tolerant to pancreatic β cells 
antigens (5), thus preventing T cell infiltration into targeted organs 
(6). AHSCT trials showed that in treated patients, an overall 
resetting of the immune system toward a “regulatory”-like T cell 
landscape was evident, with an increase in CD4+Foxp3+ Tregs (7). 
Unfortunately, the use of immunosuppression during AHSCT 
limits the potential use of this therapy in T1D to experimental 
conditions, due to patients’ potential exposure to adverse effects. 
Interestingly, the immunoregulatory properties of hematopoietic 
stem and progenitor cells (HSPCs) seem to be linked to their 
expression of the immune checkpoint-signaling molecule PD-L1 
(or CD274) (8, 9). They further express CXCR4, which allows 
HSPCs to traffic to inflamed area/sites of injuries (10). Unlike 
mesenchymal or embryonic stem cells, which are associated 
with the potential development of tumorogenesis and formation 
of ectopic tissue (5, 11–13), HSPCs have been safely used for 
years (14–16). Several studies suggested that prostaglandin E2 
(PGE2) might have anti-inflammatory effects through inhibition 
of several pro-inflammatory cytokines (17). Other investigators 
have demonstrated that the endogenous anti-inflammatory role 
of PGE2 is mainly mediated through it receptor EP4, thereby 
inhibiting macrophage derived pro-inflammatory chemokines 
production during atherogenesis (18, 19). While others have 
mainly studied in depth the mechanism by which PGE2 can 
control inflammation and demonstrated that PGE2 plays its 
regulatory role by limiting T  cell activation thereby impairing 
T  cell arrest and inhibiting T  cells interactions with dendritic 
cells (DCs) (20). Previous reports have introduced and identified 
prostaglandins (PGs) as potentials HSPCs enhancing candidates 
capable of inducing/improving their long-term maintenance and 
engraftment faculties (21). We hypothesize that enhancing the 
immunoregulatory properties of HSPCs using pharmacological 
modulation with small molecules may create a novel powerful 
immunoregulatory tool for the treatment of T1D.
MaTerials anD MeThODs
human studies
Study Population Included in the AHSCT Clinical Trial
Two cohorts consisting of 36 T1D patients were enrolled in the 
AHSCT program and were also enrolled in three independent 
clinical trials as previously described (6). Autoantibodies were 
analyzed on serum by RIA (for insulin autoantibodies) and 
ELISA (for insulinoma-2-associated autoantibodies, glutamic 
acid decarboxylase autoantibodies, and Znt8) according to the 
standard of care clinical procedure. The study was performed in 
accordance with Institutional Review Board committee approval 
of each participant Institution, informed consent was provided by 
all individuals. All baseline demographic and clinical characteris-
tics of the study population are reported in Table 1.
Study Population Included in the PG-Library 
Screening
Blood samples were obtained from long lasting T1D patients 
(n = 24) and healthy controls (CTRL) (n = 5) in accordance with 
Institutional Review Board committee approval of San Raffaele 
Hospital and of Boston children’s Hospital (BCH 3851); informed 
consent was provided by all individuals included in the present 
study. Baseline characteristics of the study population are sum-
marized in Table 2. Peripheral blood mononuclear cells (PBMCs) 
isolated from 20 ml blood samples using Lymphoprep (Stem Cell 
Technologies, Cambridge, MA, USA) were frozen in freezing 
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medium (RPMI 1640 20% FBS and 8% DMSO) and stored at 
−80°C. After thawing, PBMCs were recovered in culturing 
medium consisting of RPMI 1640 (Life Technologies, Carlsbad, 
CA, USA) supplemented with 10% FBS, 2  mM l-glutamine 
(Life Technologies), 100 U/ml penicillin (Life Technologies), for 
48 h, and CD34+ cells were then isolated using a CD34 Positive 
Isolation Kit (Miltenyi Biotec, San Diego, CA, USA) according to 
the manufacturer’s instructions.
Pharmacological Modulation of Human CD34+ Cells
1  ×  105 of isolated human CD34+ HSPCs (purity 99%) were 
cultured in 200  µl of StemSpan SFEM II media (SEMCELL 
Technologies Inc., Cambridge, MA, USA), and each compound 
in the Prostaglandin Screening Library II (Cayman Chemicals, 
Ann Arbor, MI, USA), the detailed composition of the library 
is shown in Table S1 in Supplementary Material, was added 
individually at day 0 and at day 1 at a concentration of 10 µM as 
previously reported by our group and others (9, 21). In another 
assay, isolated CD34+ cells from freshly isolated human PBMCs 
or from cryopreserved PBMCs, and processed as described 
earlier, were cultured in the presence of a cocktail of cytokines 
containing: 10  µg/ml heparin (SEMCELL Technologies Inc., 
Cambridge, MA, USA), 10  ng/ml human stem cell factor 
(SCF) (Miltenyi Biotec, San Diego, CA, USA), 20 ng/ml human 
thrombopoietin (TPO) (Miltenyi Biotec, San Diego, CA, USA), 
10 ng/ml human FGF-1 (Miltenyi Biotec, San Diego, CA, USA), 
100 ng/ml insulin-like growth factor-binding protein 2 (IGFBP2) 
(R&D Systems, Inc., Minneapolis, MN, USA), and 500  ng/ml 
angiopoietin-like 3 (R&D Systems, Inc., Minneapolis, MN, USA). 
PGE2 (PromoKine, PromoCell Gmbh, Germany) was added by 
pulsing the culture at 0, 24, 72 h and 6 days with 2 µl of diluted 
PGE2 (10 µM). Cells were cultured for 7 days at 37°C in 5% CO2, 
and CD34+ cells were then subjected to FACS analysis and were 
run on a FACSCelesta™ (Becton Dickinson, Franklin Lakes, NJ, 
USA). Data were analyzed using FlowJo software version 8.7.3 
(Treestar, Ashland, OR, USA). The different cytokines used here 
and their related concentration as well as the choice of the incuba-
tion timing was used as previously reported in the literature (22).
Quantitative Reverse Transcriptase Polymerase 
Chain Reaction (qRT-PCR)
RNA was extracted from CD34+ cells using Direct-zol™ RNA 
Kits (Zymo, Irvine, CA, USA) and Trizol Reagent (Invitrogen 
Carlsbad, CA, USA), RNA quality was assessed by Multiskan™ 
GO Microplate spectrophotometer and the ratios of absorbance 
at 260 and 280 nm were assessed for all the samples. Only samples 
with RNA ratios within 1.9 were included in the present study. 
cDNA synthesis was made from purified total RNA by reverse 
transcription using High capacity cDNA Reverse Transcription 
RETROscript® Kit (Thermo Fisher Scientific, Waltham, MA, 
USA) followed by a pre-amplification using Taqman PreAmp Kit 
(Applied Biosystems) according to the manufacturer’s instruc-
tions. qRT-PCR analysis was performed using TaqMan assays 
(Life Technologies, Grand Island, NY, USA) containing PCR 
primers and TaqMan probes according to the manufacturer’s 
instructions. Normalized expression values were determined 
using the ΔCt method. qRT-PCR data were normalized for the 
expression of GAPDH. qRT-PCR reactions were performed 
in triplicate in a 96-well format using an Applied Biosystems 
7900HT fast real-time PCR instrument. Relative expression 
was calculated using the comparative threshold cycle method 
as previously described (23, 24). For two-groupcomparisons, 
a Student’s t test was employed. Reported below are the main 
characteristics of the primers used:
gene 
symbol
assay iD refseq accession # band size 
(bp)
reference 
position
CD274 
(PD-L1)
Hs01125299_m1 NM_ 001267706.1 89 441
CD184 
(CXCR4)
Hs00237052_m1 NM_ 001008540.1 153 973
IDO1 Hs00984148_m1 NM_ 0022164.5 66 651
GAPDH Hs99999905_m1 NM_001289746.1 122 229
Human ELISPOT Assay
An ELISPOT assay was used to measure the number of IFN-γ-
producing cells according to the manufacturer’s protocol (BD 
Biosciences, San Jose, CA, USA) as previously shown by our 
group (2). 1 × 106 PBMCs isolated from T1D patients were cul-
tured for 2 days in the presence of IA-2 peptide (Thermo Fisher 
Scientific Gmbh, Germany) (100  µg/ml) in RPMI medium 
supplemented with 10% FBS. At 24 h after stimulation, 500 µl 
of medium was added to the culture. Cells were collected at day 
2 and added to plates coated with anti-IFN-γ antibody (eBio-
science, Thermo Fisher Scientific, Waltham, MA, USA) with 
or without PGE2-modulated CD34+ cells at ratios of 1:2 or 1:10 
or 1:32 in RPMI medium supplemented with 10% FBS. Spots 
were counted using an A.EL.VIS Elispot Reader (A.EL.VIS 
GmbH, Hannover, Germany) or on an Immunospot Reader 
(C.T.L. Cellular Technology Ltd., Cleveland, OH, USA).
Immunofluorescence and Confocal Microscopy
Regulatory CD34+ (PGE2-modulated) cells and unmodulated 
CD34+ cells isolated from peripheral blood of healthy controls 
were fixed in 4% PFA for 1 h at 4 C, washed three times for 20 min 
in PBS, and cells were counterstained with blue fluorescent DAPI 
(1:10,000, BioLegend, San Diego, CA, USA) and anti-human 
PD-L1 (BD Biosciences). Cells were photographed under a 63× 
objective. Images were captured on a Leica SP5X system with 
an upright DM6000 microscope and A1R confocal microscope 
(Nikon Instruments, Melville, NY, USA). Histology was evalu-
ated by at least two expert pathologist (9).
Migration Assay
Transwell migration assays were performed on PGE2-modulated 
HSPCs compared to unmodulated HSPCs in the presence of 
0–50 ng/ml SDF-1 (R&D Systems, Minneapolis, MN, USA). In 
brief, cells were suspended in 0.5% BSA Phenol Red-Free RPMI 
and plated in the upper chambers of an HTS-Transwell-96-well 
permeable support plate (Corning, Acton, MA, USA) and incu-
bated at 37°C in 5% CO2 for 2 h. After 2 h incubation, migrated 
cells were counted using BD TruCount (BD Biosciences) by flow 
cytometry.
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Murine studies
Mice
Female NOD/ShiLtJ (NOD) or non-obese diabetic mice (NOD) 
which is the commonly used model for autoimmune T1D 
studies, NOD.FVB-Tg (CAG-luc,-GFP)L2G85Chco/FathJ (Luci-
ferase NOD) mice which exhibit a widespread expression of the 
two cell tracers eGFP and firefly luciferase directed by the CAG 
promoter allowing thus an easily tracking of the cells and NOD.
CgTg (TcraBDC2.5,TcrbBDC2)1Doi/DoiJ (BDC2.5 NOD) mice 
which has the particularity to carry a rearranged TCR a and 
eight genes from a diabetogenic T cell clone, BDC2.5 and is com-
monly used in vitro autoimmune assays; were purchased from 
the Jackson Laboratory (Bar Harbor, ME, USA). All mice were 
housed under specific pathogen-free conditions at an Association 
for Assessment and Accreditation of Laboratory Animal Care 
International-accredited facility at BCH. Institutional guidelines 
and protocols were approved and adhered to the Institutional 
Animal Care and Use Committee.
Murine Regulatory KL Cell Modulation
Murine bone marrow KL (Lineage−c-Kit+) cells were isolated 
using magnetic beads and MACS® separation columns (Miltenyi 
Biotec, San Diego, CA, USA) and ~2 × 105 cells were plated in 
a U-bottomed 96-well plate with 200  µl of stem cell medium, 
Stemspan-SFEMII (STEMCELL Technologies, Cambridge, MA, 
USA) and PGE2 (PromoKine, PromoCell Gmbh, Germany) was 
added at day 0 and day 1, at a concentration of 10 µM.
Flow Cytometric Analysis and Intracellular Cytokine 
Staining
Flow cytometry was performed to analyze surface expression 
markers of PGE2-modulated HSPCs and dmPGE2 (16, 16-dime-
thyl PGE2)-modulated HSPCs. Anti-mouse PD-L1, PD-L2, 
PD-1, CD40, CD80, CD86, CD4, CD8, Ly-6G (Gr-1), B220, CD3, 
CXCR4, CCR2, CCR4, CCR5, CCR6, CCR7, CCR8, CXCR3, 
IL-4, IL-10, and IFN-γ were purchased from BD Biosciences, 
eBioscience (San Diego, CA, USA) and BioLegend. The follow-
ing antibodies corresponded to isotype controls for the murine 
antibodies above: PE mouse IgG1, κ isotype ctrl, Armenian ham-
ster IgG; APC mouse IgG2b, κ isotype ctrl, Armenian hamster 
IgG. Cells were subjected to FACS analysis and were run on a 
FACSCalibur™ (Becton Dickinson). Data were analyzed using 
FlowJo software version 8.7.3 (Treestar).
Intracellular Staining for Flow Cytometry
Naïve CD4+CD25− T cells (5 × 105) were isolated from BDC2.5 
TCR tg mice with a negative selection strategy using a CD4+ 
CD25+ Regulatory T cell isolation kit (Miltenyi Biotec) and were 
stimulated with BDC2.5 peptides and CD11c+ DCs (2.5 × 105) 
previously isolated using CD11c+ mAb-coated microbeads. DCs 
were added at a 1:2 ratio to T  cells and were cocultured with 
PGE2-modulated KL cells (PGE2-KL) at ratios of 1:1, 5:1, and 
10:1 (ratio of T  cells to PGE2-KL) or alone (controls) or with 
untransduced KL cells for 24 h in RPMI 10% FBS in a humidified 
incubator at 37°C, 5% CO2. After incubation, cells were collected, 
washed, and plated in RPMI 10% FBS, then stimulated with 
50 ng/ml PMA (Sigma Aldrich, St. Louis, MO, USA), 750 ng/ml 
ionomycin (Sigma Aldrich) and the protein transport inhibitor 
BD GolgiStop (6 μl per 6 ml of RPMI as recommended by the 
manufacturer, BD Biosciences) for 5 h in a humidified incubator 
at 37°C, 5% CO2. After incubation, cells were collected, washed, 
stained for surface marker CD4 APC, followed by washing 
and permeabilization using the BD Cytofix/Cytoperm Kit (BD 
Biosciences) and staining with anti-mouse IFN-γ (eBioscience). 
Finally, CD4+ IFN-γ+ cells were assessed by flow cytometric 
analysis.
Pancreas Digestion and Preparation for Flow 
Cytometry
Pancreata were collected in ice-cold IMDM medium, cut into 
small pieces, and digested with Collagenase D for 1 h at 37°C, 
with DNase I added after 30 min. Digested pancreata were passed 
through a 70-µm cell strainer to obtain single cell suspensions 
and then analyzed by flow cytometry. For tracking GFP+ cells, 
biotinylated anti-GFP (BD Biosciences) was used at 20  μg/ml 
followed by staining with APC-conjugated streptavidin (BD 
Biosciences).
statistical analysis
Statistical analysis was performed using an unpaired Student’s t 
test. A two-sided value of P ≤ 0.05 was considered statistically 
significant. All graphs were generated using GraphPad Prism 
software version 5.0b (GraphPad Software, Inc., La Jolla, CA, 
USA). All statistical tests were performed at the 5% significance 
level.
resUlTs
ahscT improves β cell Function in 
Treated T1D Patients
Two cohorts consisting of 36 T1D patients were enrolled in the 
AHSCT program and were also enrolled in three independent 
clinical trials as previously described (6). All baseline demographic 
and clinical characteristics of the study population are reported 
in Table 1. The patient group was predominantly male (27 males 
and 9 females) with a mean age of 22.4 years and a short history 
of disease duration (within 6 weeks of diagnosis), confirmed by 
the presence of autoantibodies to islet peptides [glutamic acid 
decarboxylase antibodies (anti-GAD) were detected in 86% of 
patients, while other autoantibodies were detected in 17% of 
patients]. Most of the patients studied (67%) had no previous his-
tory of diabetic ketoacidosis/ketosis. The mean body mass index 
of patients at diagnosis was 20.7 ± 0.5 (kg/m2 ± SEM), and their 
mean glycated hemoglobin of (HbA1c) was 86.6 ± 6.4 (mmol/
mol ±  SEM). All patients underwent a stem cell mobilization 
protocol as previously described (6) with cyclophosphamide 
(2 g/m2) and granulocyte colony-stimulating factor (5–10 µg/kg) 
daily, beginning the day after cyclophosphamide administration 
(6). A mean dose of 5.8 ± 0.8 × 106/kg cryopreserved CD34+ cells 
was administered as a single infusion at day 0 (6). All patients 
showed improvement in β cell function, as revealed by an increase 
in C-peptide levels over time, which reached a persistent and 
FigUre 1 | Non-myeloablative AHSCT preserved pancreatic β cell function in patients newly diagnosed with T1D. (a) Line graph showing 2 h peak-stimulated 
C-peptide levels after a mixed meal tolerance test following AHSCT, at 12 and 24 months of follow-up. (b) Correlation between the number of HSPCs injected 
during AHSCT and 2 h peak-stimulated C-peptide levels evaluated at 6 months of follow-up. (c,D) Correlation between the number of hematopoietic stem cells 
(HSPCs) injected during AHSCT and EIR evaluated at 8 months (c) and 12 months (D) of follow-up. All data are expressed as mean ± SEM. All parameters 
examined were statistically significantly different when comparing baseline values vs. those at 6, 8, and 12 months. *P < 0.05, **P < 0.001. Abbreviations: AHSCT, 
autologous hematopoietic stem and progenitor cell transplantation; UI, units of insulin; EIR, exogenous insulin requirement units; HSPCs, hematopoietic stem and 
progenitor cells; T1D, type 1 diabetes.
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stable median value >2.5 ng/ml at 12 months of follow-up and 
lasted until 24 months after treatment (Figure 1A). Interestingly, 
compared to pre-AHSCT treatment levels, 2 h postprandial peak-
stimulated C-peptide levels increased significantly at 6 months 
post-AHSCT treatment and reached ~2.7 ng/ml at 24 months of 
follow-up (Figure 1A). Furthermore, a significant positive cor-
relation, albeit weak, was found between the number of CD34+ 
cells infused and C-peptide levels at 6  months after treatment 
(Figure  1B). Statistical analysis revealed a significant negative 
correlation between the number of CD34+ cells injected during 
AHSCT and exogenous insulin requirement units evaluated at 
8 months (Figure 1C) and 12 months (Figure 1D) of follow-up. 
T1D patients treated with autologous hematopoietic stem cell 
transplantation showed an overall improvement in glycometa-
bolic control and maintenance of β cell function.
Pg library screening
Prostaglandin E2 has been described as a small molecule known 
to enhance the homing and engraftment of HSPCs. We therefore 
sought to screen all known types of PGs using the Prostaglandin 
Screening Library II, which contains 64 small molecules. We first 
screened each small molecule contained in the library for its 
capacity to upregulate PD-L1 in human CD34+ cells isolated 
from T1D patients (Figures  2A,B). CD34+ cells isolated from 
T1D patients were cultured in StemSpan SFEMII and pulsed 
with each PG small molecule contained in the aforementioned 
library at a concentration of 10 µM at 24 and 48 h. Using FACS 
analysis, we calculated the mean fluorescence intensity of PD-L1 
expression following treatment with each small molecule used 
to modulate CD34+ cells as compared to untreated/unmodulated 
CD34+ cells (Figure 2B). We generated a heat map depicting the 
degree to which each PG small molecule affected PD-L1 expres-
sion on CD34+ cells (Figure 2B), thus allowing us to evaluate PG 
candidates. Based on its ability to modulate PD-L1 expression, 
we selected PGE2 as a candidate for further study; in addition, 
PGE2 has been described in the literature and has been tested 
in clinical trials as a potential therapy for enhancing HSPC 
engraftment following cord blood transplantation (21). Isolated 
CD34+ cells from healthy control patients (CTRL) and from 
T1D patients were cultured in StemSpan SFEMII and pulsed 
with 10 µM of PGE2 at 24 and 48 h. We first tested the effect of 
pharmacological modulation with PGE2 by FACS analysis, and 
our data revealed a slight increase in PD-L1 expression, although 
not significant, in cultured CD34+ cells from T1D and healthy 
FigUre 2 | Prostaglandins (PGs) enhance PD-L1 expression on human CD34+ cells. (a,b) Results of screening of a PG small molecule library tested for the ability 
to upregulate PD-L1 (MFI) on CD34+ cells obtained from T1D patients. The schematic of the experimental design is shown in (a). The 3-color coding shown in  
(b) represents lowest PD-L1 MFI values (blue), median PD-L1 MFI values (pink), and highest PD-L1 MFI values (red). (c,D) Representative flow cytometric analysis 
and quantitative bar graph of PD-L1 expression on CD34+ cells from T1D patients pre- and post-pharmacologic modulation with PGE2 as compared to CD34+  
cells obtained from healthy controls. (e) PD-L1 and CXCR4 expression (mRNA) fold change was quantified for CD34+ cells pre- and post-modulation with PGE2.  
(F) Migration assay using CD34+ cells pre- and post-modulation with PGE2. (g) Confocal imaging of CD34+ cells pre- and post-modulation with PGE2, showing 
DAPI (in blue) and PD-L1 (in green) staining. 63× magnification. Scale bar, 50 µm. (h) IDO-1 expression (mRNA) fold change was quantified for CD34+ cells pre- and 
post-modulation with PGE2. (i,J) Representative flow cytometric analysis (i) and quantitative bar graph (J) of PD-L1 expression on CD34+ cells from T1D patients 
pre- and post-pharmacologic modulation with four small molecule PGE2 agonists. All data are expressed as mean ± SEM. *P < 0.05, **P < 0.001. Abbreviations: 
MFI, mean fluorescence intensity; T1D, type 1 diabetes; PGE2, prostaglandin E2.
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control patients, with the latter showing a higher percentage 
of PD-L1 expression as compared to cells from T1D patients 
(Figures 2C,D). This pattern was further confirmed by confocal 
imaging, in which PD-L1 surface expression was upregulated in 
PGE2-treated CD34+ cells as compared to untreated (Figure 2G). 
Similar results were obtained by RT-PCR, which demonstrated a 
slight increase (although not significant) in PD-L1 expression in 
CD34+ cells upon modulation with PGE2 (Figure 2E). Notably, 
RT-PCR showed a twofold increase of CXCR4 gene expression, 
a protein required for the homing of HSPCs, in PGE2-treated 
CD34+ cells as compared to untreated (Figure 2E). We therefore 
sought to perform a migration assay in order to assess the homing 
properties of PGE2-treated CD34+ cells (Figure  2F). Our data 
confirmed a substantial increase in the homing potential of 
PGE2-treated CD34+ cells (Figure 2F). The expression of another 
relevant immunoregulatory protein, IDO-1, remained unchanged 
post-pharmacologic modulation with PGE2 (Figure  2H). We 
next selected the four PG small molecules [16,16-dimethyl 
PGE2, 16,16-dimethyl PGE2 4-(4-acetamidobenzamido) phenyl 
ester, 6-keto PGE1 and 20-ethyl PGE2] that showed the strong-
est capacity to upregulate PD-L1, based on the results obtained 
from library screening (Figures  2I,J). By a PGE2-analog and 
two competitive inhibitors of 15-hydroxy PG dehydrogenase, 
which possess a prolonged half-life in  vivo [16,16-dimethyl 
PGE2, 16,16-dimethyl PGE2 4-(4-acetamidobenzamido) phe-
nyl ester and 20-ethyl PGE2]. FACS analysis of PD-L1 protein 
expression following pharmacologic modulation with these four 
PGs (Figures 2I,J) demonstrated robust upregulation of PD-L1 
FigUre 3 | Effects of human PGE2-modulated and cytokine-treated CD34+ cells. (a,b) Sustained and robust upregulation of PD-L1 upon culture for 7 days with 
PGE2 and a cocktail of cytokines (heparin, human SCF, human TPO, human FGF-1, IGFBP2, and Angptl3) on CD34+ cells obtained from T1D patients as compared 
to those from healthy controls. (c) Effect of PGE2 pulsing on CD34+ cells cultured for 0, 24, 72 h and 6 days on PD-L1 expression on CD34+ cells. (D,e) Bar graphs 
showing an increase in the number of PD-L1+ CD34+ cells and fold increase in cell number after 7 days of culture with PGE2 supplemented with cytokines.  
(F,g) Upregulation of PD-L1 expression following culture with PGE2 (shown as percentage) on CD34+ cells was not altered by the freeze/thawing process.  
(h) PGE2-modulated CD34+ cells abrogate the IFN-γ autoimmune response to insulin-associated 2 (I-A2) autoantigen in vitro, as measured via the quantification of 
IFN-γ-producing cells in an Elispot assay; Diftavax refers to a vaccine including immunization against tetanus toxoid, difteria, and hemophilus. (i) PGE2-modulated 
CD34+ cells and PGE2-modulated CD34+ cells cultured for 7 days in STFIA media abrogate the IFN-γ autoimmune response toward insulin-associated 2 (I-A2) 
autoantigen in vitro, as measured via the quantification of IFN-γ-producing cells in an Elispot assay, even when added at low dose. (J) PGE2-modulated CD34+ cells 
abrogate the anti-CD3/CD28-stimulated PBMC response in vitro as measured via the quantification of IFN-γ-producing cells in an Elispot assay. Data are expressed 
as mean ± SEM. Data are representative of at least two independent experiments. *P < 0.05; **P < 0.01. Abbreviations: SCF, stem cell factor; TPO, thrombopoietin; 
hFGF-1, human fibroblast growth factor 1; IGFBP2, insulin-like growth factor-binding protein 2; Angptl3, angiopoietin-like 3; PBMCs, peripheral blood mononuclear 
cells; PGE2, prostaglandin E2; T1D, type 1 diabetes.
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expression. These results were further confirmed by RT-PCR, 
which showed a marked upregulation of PD-L1 mRNA follow-
ing pharmacological modulation with 16,16-dimethyl PGE2, 
16,16-dimethyl PGE2 4-(4-acetamidobenzamido) phenyl ester 
and 20-ethyl PGE2 (data not shown).
Pge2 highly augments PD-l1 expression 
in human hsPcs When supplemented 
With hematopoietic cytokines
In order to improve the strategy used for HSPC expansion 
and to enhance the function of PGE2-modulated HSPC, we 
added hematopoietic cytokines (SCF, TPO, FGF-1, IGFBP-2, 
and Angptl-3 proteins) known as a potent cocktail for HSPC 
maintenance, into our established culture conditions (22). 
Isolated CD34+ cells (HSPCs) obtained from T1D patients and 
from healthy controls were cultured using StemSpan SFEMII 
supplemented with the aforementioned human stem cell growth 
factors (STFIA medium) and pulsed with PGE2 (10  µM) at 
24, 96  h and at 7  days at 37°C 5% CO2. PD-L1+ HSPCs were 
then quantified by FACS analysis at different time points post-
culture. After 7  days, a ~5-fold increase in the percentage of 
PD-L1+CD34+ cells was evident in human HSPCs obtained from 
T1D, with a similar albeit much less pronounced increase in the 
percentage of PD-L1+CD34+ cells obtained from healthy control 
patients (~2-fold increase) (Figures 3A–E). We next determined 
whether freezing/cryopreservation has any effect on PD-L1 
expression, by comparing freshly isolated HSPCs with frozen 
FigUre 4 | Profile of murine KL cells. (a,b) Representative flow cytometric analysis and quantitative bar graph of PD-L1 expression on Lineage−c-kit+ (KL) cells 
from NOD mice pre- and post-pharmacologic modulation with PGE2. (c,D) Representative flow cytometric analysis and quantitative bar graph of CXCR4 
expression on KL cells from NOD mice pre- and post-pharmacologic modulation with PGE2. (e) Quantitative bar graph of flow cytometric expression of positive 
and negative costimulatory molecules (CD40, CD80, CD86, PD-L1, PD-L2, and PD-1) and of select pro-inflammatory and anti-inflammatory cytokines (IFN-γ, 
IL-10, and IL-4) in PGE2-modulated KL cells (PGE2-KL) from NOD mice as compared to those modulated with a selected PGE2 clinical grade agonist (dmPGE2) 
and compared to unmodulated KL cells isolated from the bone marrow of normoglycemic NOD mice. (F) Flow cytometric expression of selected chemokine 
receptors (CXCR4, CCR2, CCR4, CCR5, CCR6, CCR7, CCR8, and CXCR3) in PGE2-KL from NOD mice as compared to those modulated with a selected PGE2 
clinical grade agonist (dmPGE2) and to unmodulated KL cells isolated from the bone marrow of normoglycemic NOD mice. (g) Quantitative bar graph of flow 
cytometric expression of chemokines receptors (CCR2, CCR4, CCR5, CCR6, CCR7, CCR8, CXCR3, and CXCR4) in PGE2-KL from NOD mice as compared to 
those modulated with a selected PGE2 clinical grade agonist (dmPGE2) and compared to unmodulated KL cells isolated from the bone marrow of normoglycemic 
NOD mice. Data are expressed as mean ± SEM. Data are representative of at least two independent experiments. *P < 0.05; **P < 0.01; ***P < 0.001. 
Abbreviations: KL, Lineage−c-kit+ cells; PGE2, prostaglandin E2.
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HSPCs, after 7 days of culture using STFIA media pulsed with 
PGE2 (Figures  3F,G). We observed sustained and conserved 
PD-L1 expression pre- and post-cryopreservation, suggesting 
that storage of HSPCs has no detrimental impact on their ex vivo 
expansion.
Pge2-Modulated human hsPcs abrogate 
the autoimmune response Ex Vivo
To study the ex vivo immunoregulatory effects of PGE2 modula-
tion as well as whether cytokine treatment enhances these effects, 
we performed an autoimmune assay using unmodulated CD34+ 
cells, PGE2-modulated CD34+ cells, or PGE2-modulated HSPCs 
cultured for 7 days in STFIA medium. CD34-depleted PBMCs 
were cocultured with control CD34+ cells (unmodulated), PGE2- 
modulated CD34+ cells, or STFIA medium-cultured PGE2-
modulated human CD34+ cells in the presence of insulin- 
associated autoantigen-2 (I-A2) peptide at different cell ratios (1:2, 
1:8, and 1:32 CD34+ cells to PBMCs), and the number of 
IFN-γ-producing cells was quantified using an ELISPOT assay 
(Figures  3H,I). Interestingly, addition of PGE2-modulated 
human CD34+ cells resulted in a significant decrease in the 
number of IFN-γ-producing cells (Figure  3H), suggesting 
that PGE2-modulated CD34+ cells are endowed with immu-
noregulatory activity ex vivo. Addition of PGE2-modulated 
FigUre 5 | PD-1 expression on murine T cells. (a,b) Representative flow 
cytometric analysis (a) and quantitative bar graph (b) for PD-1+CD4+ T cells 
isolated from splenocytes of NOD mice as compared those from C57BL/6 
mice. (c,D) Representative flow cytometric analysis (c) and quantitative bar 
graph (D) for PD-1+CD8+ T cells isolated from splenocytes of NOD mice as 
compared those from C57BL/6 mice.
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CD34+ cells cultured for 7  days in STFIA medium showed a 
further abrogation of the autoimmune response, and this effect 
was observed even when cells were added at a very low ratio 
(1:32) to PBMCs (Figure  3I). The effects of PGE2-modulated 
CD34+ cells cultured for 7  days in STFIA media were further 
confirmed in a nonautoimmune-specific anti-CD3/anti-CD28 
assay (Figure 3J).
Murine Pge2-Modulated hsPcs abrogate 
the autoimmune response In Vitro
We next explored the feasibility of pharmacological modula-
tion of PD-L1 with PGE2 in murine HSPCs. FACS analysis 
showed an upregulation of PD-L1 post-PGE2 modulation in 
KL (Lineage−c-Kit+) cells isolated from bone marrow of NOD 
mice (Figures  4A,B). Furthermore, we assessed PD-1 on T 
cells from NOD mice as compared to those from C57BL/6 and 
our data showed a significant defect in PD-1 expression on 
CD4 T cells isolated from NOD mice (Figure 5). Interestingly, 
another protein, CXCR4, primary involved in the homing of 
HSPCs, was markedly upregulated (Figures  4C,D). We then 
analyzed the expression of costimulatory molecules, as well as 
pro-inflammatory and anti-inflammatory cytokines by flow 
cytometry, which demonstrated upregulation of PD-L2, PD-1, 
CD80, and CD40 in PGE2-KL as compared to unmodulated KL 
cells. The expression of these molecules in KL cells modulated 
with dmPGE2 (known as 16, 16-dimethyl PGE2, a molecule 
which exerts a prolonged effect in vivo as compared to PGE2) 
was similarly upregulated (Figure 4E). Moreover, we explored 
the chemokine receptor profile of PGE2-KL as compared to 
dmPGE2-modulated KL cells and unmodulated KL cells in 
order to assess which chemokines are potentially involved in 
the homing of PGE2-modulated and dmPGE2-modulated KL 
cells. Consistent with the results in Figure 4C, CXCR4 was the 
most expressed chemokine in both groups of KL cells treated 
with PGE2 and dmPGE2 (Figures 4F,G). We next explored the 
immunoregulatory properties of PGE2-KL in an autoimmune 
setting in  vitro. PGE2-KL generated from normoglycemic 
NOD mice were cocultured at ratios of 1:1, 1:5, and 1:10 (KL 
cells to T  cells) with CD11c+ DCs and BDC2.5 transgenic 
CD4+CD25− T  cells in the presence of BDC2.5 peptide. 
Quantification by flow cytometry revealed a pronounced and 
significant decrease in the percentage of IFN-γ+CD4+ T  cells 
when PGE2-KL were added to the assay as compared to when 
unmodulated KL cells were used (Figures  6A,B). Indeed, 
PGE2-KL exerted a robust immunoregulatory effect even if 
added at low ratios (1:5 PGE2-treated KL cell to T  cells). A 
less pronounced effect was observed when unmodulated 
KL were added to the assays. Interestingly, the percentage of 
activated CD4+CD25+ T  cells declined upon coculture with 
KL or PGE2-KL (Figure  6C). PGE2-modulated HSPCs are 
thus endowed with immunoregulatory properties and are 
capable of abrogating the autoimmune response in vitro.
adoptively Transferred Murine Pge2-
Modulated hsPcs Traffic to inflamed 
areas
To examine the trafficking properties of GFP+ PD-L1-expressing 
KL cells in an in vivo inflammatory setting, we performed a set of 
tracking experiments in NOD mice. Following infusion of GFP+ 
KL cells extracted from the bone marrow of Luciferase NOD-
GFP mice and treated with PGE2 as previously described, the 
pancreas and pancreatic draining lymph nodes (PLN) of NOD 
mice were harvested at 24 h. GFP+ cells were quantified in the 
aforementioned tissues by flow cytometry and were detectable 
in the PLN (Figure  6D) and in the pancreata of NOD mice 
(Figure  6E). The phenotype of the GFP+ cells after adoptive 
transfer and after homing to the pancreata of NOD mice showed 
Gr-1 expression, indicative of myeloid lineage, while very few 
cells were CD3+ (Figure  6E). These GFP+ PD-L1-expressing 
cells might probably interact with autoreactive CD4 and CD8 
T cells.
DiscUssiOn
The prospect of successful cell therapy has recently gained 
greater footing in the medical landscape in the past 2 years with 
the arrival of many cell-based products. Recently, many AHSCT-
related clinical trials have demonstrated a beneficial effect in the 
treatment of several autoimmune diseases, and AHSCT is now 
considered one of the few therapies capable of reversing T1D in 
humans (6, 14, 25–27). In our study, we observed preservation of 
FigUre 6 | Effects of murine KL cells. (a,b) Representative flow cytometric analysis (a) and quantitative bar graph (b) for IFN-γ+CD4+ T cells isolated from 
NOD-BDC2.5 TCR Tg mice and stimulated with BDC2.5 peptide in the presence of DCs (Control) or upon coculture with unmodulated KL or with PGE2-KL (at 
different ratios). (c) Quantitative bar graph of the percentage of CD4+ T cells upon coculture with KL or PGE2-KL. (D) Representative flow cytometric analysis of 
GFP+PGE2-KL in the PLN of treated NOD mice following 24 h of treatment with GFP+PGE2-KL, demonstrating that they traffic to the PLN following adoptive 
transfer into NOD mice. (e) Representative flow cytometric analysis of GFP+PGE2-KL in the pancreas of NOD mice 24 h post-infusion with GFP+PGE2-KL, 
demonstrating the surface phenotype of GFP+ cells. Abbreviations: KL, Lineage−c-kit+ cells; PGE2-KL, PGE2-modulated KL cells; HSPCs, hematopoietic stem  
and progenitor cells; GFP, green fluorescent protein; PGE2, prostaglandin E2; DCs, dendritic cells.
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β cell function following AHSCT, as most patients included in our 
study population exhibited a sustained and adequate postprandial 
C-peptide response. The majority of these patients achieved and 
maintained peak-stimulated C-peptide levels higher than 0.6 ng/ml 
for at least 2 years of follow-up. Sustained C-peptide secretion 
is known to be associated with reduced prevalence (~30%) of 
hypoglycemic events and with a slower progression of diabetes 
complications, as reported by the DCCT Trial (28). Several 
patients also experienced reversal of the disease or a decrease 
in the exogenous insulin daily requirement. Although these are 
very encouraging results, many investigators have reported vari-
ous complications and adverse effects associated with AHSCT in 
T1D patients, primarily related to the effects of immunosuppres-
sion (6). Some patients experience only temporary remission, 
and thus achieving prolonged remission of the disease remains 
the foremost goal for future clinical trials. Recently, much 
progress has been made with regard to the identification of 
small molecules and growth factors capable of both enhancing 
HSPC proliferation (15, 16) and further expanding the immu-
nomodulatory subsets of HSPCs, in order to capitalize on their 
immunosuppressive properties. Interestingly, a screening study 
performed in zebrafish embryos showed that PGE2 enhances 
HSPC expansion and facilitates HSPC engraftment after bone 
marrow transplantation (21). Investigating and determining the 
effects of ex vivo modulation of HSPCs with PGE2 in an autoim-
mune setting may provide insight with regard to how to robustly 
enhance their immunoregulatory properties. Our screening 
results performed on ~64 known PGs allowed us to select four 
PGs, which are analogs to PGE2 and which we show induce rela-
tively high upregulation of PD-L1 expression on human CD34+ 
cells. We therefore sought to test the ability of PGE2-modulated 
HSPCs to affect the autoimmune response in vitro. Compared to 
unmodulated HSPCs, HSPCs overexpressing PD-L1 successfully 
abrogated the human autoimmune response in vitro. Next, we 
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sought to explore whether refining the ex vivo culture approach 
by including a cocktail of potent cytokines important for HSPC 
maintenance and extending the length of culture to 7  days 
could enhance the effects observed. Importantly, this approach 
remarkably enhanced the immunoregulatory properties of 
HSPCs and induced more pronounced PD-L1 expression. This 
expression appeared to be stable, unaffected by the freeze/thaw 
process, and resulted in a potent abrogation of the autoimmune 
response by modulated HSPCs, even when added at a very low 
ratio to T  cells. Paralleling the human data, these preclinical 
murine studies also confirmed that PGE2-modulated HSPCs 
similarly exhibited immunoregulatory effects, as they markedly 
abrogated CD4-restricted autoimmune responses in vitro. In vivo 
tracking studies suggested that PGE2-modulated HSPCs home 
to the inflamed pancreas and PLN of NOD mice, most likely due 
to their substantial expression of CXCR4 (9). Based on the data 
herein, ex vivo expansion strategies with PGE2 combined with 
hematopoietic cytokines could generate a novel immunoregula-
tory HSPC-based approach potentially useful in the treatment 
of autoimmune T1D, without the detrimental effect of immu-
nosuppressive agent toxicity, which is observed with standard 
immunotherapy. The recent discovery that a pre-established 
suicide genetic system may control survival and prevent toxicity 
of HSPCs undergoing ex vivo expansion will implement their use 
in clinical settings, allowing for easier manipulation of HSPCs 
and for a cell therapy-based approach in immune-mediated 
disorders (29).
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